PMID- 28841827
OWN - NLM
STAT- MEDLINE
DCOM- 20171206
LR  - 20220317
IS  - 1471-2415 (Electronic)
IS  - 1471-2415 (Linking)
VI  - 17
IP  - 1
DP  - 2017 Aug 25
TI  - Comparison of 12-month therapeutic effect of conbercept and ranibizumab for 
      diabetic macular edema: a real-life clinical practice study.
PG  - 158
LID - 10.1186/s12886-017-0554-8 [doi]
LID - 158
AB  - BACKGROUND: To compare the efficacy of intravitreal conbercept and ranibizumab in 
      the treatment of diabetic macular edema (DME) in a real-life clinical practice. 
      METHODS: This was a retrospective study. Among 62 Chinese patients with DME, 32 
      patients (36 eyes) received intravitreal conbercept (IVC) injections and 30 
      patients (32 eyes) received intravitreal ranibizumab (IVR) injections, once a 
      month for 3 months followed by as needed therapy. All participants had at least 
      12 months of follow-up. We compared the changes in best-corrected visual acuity 
      (BCVA) letter score and central retinal thickness (CRT) between groups, as well 
      as the number of intravitreal injections delivered. Safety was assessed with the 
      incidence of adverse events (AEs). RESULTS: At month 12, the mean BCVA letter 
      score improved by 9.3 +/- 5.2 with conbercept, and by 8.9 +/- 4.4 with ranibizumab, 
      the mean CRT reduction was 138.4 +/- 97.7 mum and 145.2 +/- 72.5 mum, respectively. 
      There was no statistically significant difference of improvement in BCVA 
      (P = 0.756) and decrease in CRT (P = 0.748) between the two groups. The number of 
      intravitreal injections delivered was significantly higher (P = 0.027) in the IVR 
      group (7.2 +/- 1.0 per eye) than in the IVC group (6.6 +/- 0.9 per eye). There were 
      no severe ocular adverse reactions or systemic adverse events. CONCLUSIONS: Both 
      conbercept and ranibizumab are effective in the treatment of DME, achieving the 
      similar clinical efficacy. In comparison to ranibizumab, conbercept shows a 
      longer treatment interval and fewer intravitreal conbercept injections are 
      needed.
FAU - Xu, Yule
AU  - Xu Y
AD  - Department of Ophthalmology, Tongji Hospital, Tongji University School of 
      Medicine, 389 Xincun Road, Shanghai, 200065, China.
FAU - Rong, Ao
AU  - Rong A
AUID- ORCID: 0000-0002-7776-3693
AD  - Department of Ophthalmology, Tongji Hospital, Tongji University School of 
      Medicine, 389 Xincun Road, Shanghai, 200065, China. rongao@163.com.
FAU - Xu, Wei
AU  - Xu W
AD  - Department of Ophthalmology, Tongji Hospital, Tongji University School of 
      Medicine, 389 Xincun Road, Shanghai, 200065, China.
FAU - Niu, Yunli
AU  - Niu Y
AD  - Department of Ophthalmology, Tongji Hospital, Tongji University School of 
      Medicine, 389 Xincun Road, Shanghai, 200065, China.
FAU - Wang, Zhen
AU  - Wang Z
AD  - Department of Ophthalmology, Tongji Hospital, Tongji University School of 
      Medicine, 389 Xincun Road, Shanghai, 200065, China.
LA  - eng
PT  - Clinical Study
PT  - Journal Article
DEP - 20170825
PL  - England
TA  - BMC Ophthalmol
JT  - BMC ophthalmology
JID - 100967802
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 1P05PW62F3 (KH902 fusion protein)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Diabetic Retinopathy/*drug therapy
MH  - Female
MH  - Humans
MH  - Intravitreal Injections
MH  - Macular Edema/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Ranibizumab/*therapeutic use
MH  - Recombinant Fusion Proteins/*therapeutic use
MH  - Retrospective Studies
MH  - Tomography, Optical Coherence
MH  - Visual Acuity
PMC - PMC6389086
OTO - NOTNLM
OT  - Conbercept
OT  - Diabetic retinopathy
OT  - Macular edema
OT  - Ranibizumab
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The study was conducted according to 
      the tenets of the Declaration of Helsinki and was approved by the Review 
      Board/Ethics committee of the Tongji Hospital. CONSENT FOR PUBLICATION: Not 
      applicable. COMPETING INTERESTS: The authors declare that they have no competing 
      interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to 
      jurisdictional claims in published maps and institutional affiliations.
EDAT- 2017/08/27 06:00
MHDA- 2017/12/07 06:00
PMCR- 2017/08/25
CRDT- 2017/08/27 06:00
PHST- 2016/11/17 00:00 [received]
PHST- 2017/08/21 00:00 [accepted]
PHST- 2017/08/27 06:00 [entrez]
PHST- 2017/08/27 06:00 [pubmed]
PHST- 2017/12/07 06:00 [medline]
PHST- 2017/08/25 00:00 [pmc-release]
AID - 10.1186/s12886-017-0554-8 [pii]
AID - 554 [pii]
AID - 10.1186/s12886-017-0554-8 [doi]
PST - epublish
SO  - BMC Ophthalmol. 2017 Aug 25;17(1):158. doi: 10.1186/s12886-017-0554-8.